Ophthalmic Prostaglandins
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Massachusetts Policy 346 alerts
Get alerted when Policy 346 changes without checking for updates manually.
Monitor payer policy activity
This policy governs step-therapy coverage for ophthalmic prostaglandins under BCBSMA commercial prescription drug plans. It applies to participating Commercial members with BCBSMA formularies, including HMO/POS, PPO/EPO, Indemnity, MEDEX with Rx, and Managed Blue for Seniors, but not Medicare Advantage.
Rescula was removed from the policy because it was removed from the market.
The 2026 annual review updated policy formatting and references without changing the criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.